Equities analysts expect Theravance Biopharma Inc (NASDAQ:TBPH) to announce sales of $17.58 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Theravance Biopharma’s earnings. The lowest sales estimate is $11.50 million and the highest is $32.30 million. Theravance Biopharma posted sales of $15.74 million in the same quarter last year, which would indicate a positive year over year growth rate of 11.7%. The company is expected to issue its next quarterly earnings report on Tuesday, February 25th.
On average, analysts expect that Theravance Biopharma will report full-year sales of $61.26 million for the current financial year, with estimates ranging from $55.00 million to $76.20 million. For the next year, analysts expect that the company will post sales of $94.22 million, with estimates ranging from $74.18 million to $129.80 million. Zacks’ sales averages are an average based on a survey of research firms that cover Theravance Biopharma.
Theravance Biopharma (NASDAQ:TBPH) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, meeting the consensus estimate of ($1.05). The firm had revenue of $12.43 million during the quarter, compared to analysts’ expectations of $13.33 million.
Shares of NASDAQ TBPH traded up $1.93 during mid-day trading on Wednesday, reaching $21.15. The company had a trading volume of 435,258 shares, compared to its average volume of 251,217. Theravance Biopharma has a 52-week low of $15.18 and a 52-week high of $29.45. The stock has a market cap of $1.03 billion, a P/E ratio of -5.30 and a beta of 1.66. The firm has a 50 day simple moving average of $17.36 and a two-hundred day simple moving average of $18.77.
A number of institutional investors have recently bought and sold shares of TBPH. Vanguard Group Inc. increased its holdings in Theravance Biopharma by 1.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,932,787 shares of the biopharmaceutical company’s stock valued at $64,223,000 after purchasing an additional 54,562 shares during the period. BlackRock Inc. grew its position in shares of Theravance Biopharma by 3.1% during the second quarter. BlackRock Inc. now owns 3,832,682 shares of the biopharmaceutical company’s stock valued at $62,587,000 after purchasing an additional 116,009 shares in the last quarter. State Street Corp lifted its holdings in shares of Theravance Biopharma by 1.0% in the 3rd quarter. State Street Corp now owns 947,616 shares of the biopharmaceutical company’s stock valued at $18,460,000 after acquiring an additional 9,112 shares during the last quarter. Northern Trust Corp raised its stake in shares of Theravance Biopharma by 0.6% during the second quarter. Northern Trust Corp now owns 553,629 shares of the biopharmaceutical company’s stock valued at $9,041,000 after acquiring an additional 3,547 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. increased its holdings in Theravance Biopharma by 15.3% during the second quarter. Jacobs Levy Equity Management Inc. now owns 309,873 shares of the biopharmaceutical company’s stock valued at $5,060,000 after buying an additional 41,060 shares during the period. Institutional investors and hedge funds own 79.64% of the company’s stock.
Theravance Biopharma Company Profile
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant.
Featured Story: How is a price target determined?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.